Tokyo, Japan, July 31, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, collectively with its affiliates, hereinafter called “Astellas”) announced the launch of the Real World Informatics and Analytics (RWI) function, effective July 1, 2015. The RWI function is headquartered in Northbrook, Illinois, the United States, with employees located in all regions. Nathan R. Crisel, formerly Director, Corporate Strategy and Planning and SIM, Astellas US LLC, leads the new function and reports directly to Chief Strategy Officer, Kenji Yasukawa, Ph.D.

In the changing healthcare environment, the digitization of healthcare data – often referred to as “big data” in healthcare, but more precisely described as “real-world data” – is one of the major strategic issues across value chain through all phases of product lifecycle in the healthcare industry. In order to enable Astellas to fully realize opportunities in this field, the RWI function was launched.

The mission of the RWI function is to better serve patients by maximizing the application, efficiency and effectiveness of real-world informatics and analytics in Astellas through dedicated internal resources. This will be a collaborative effort, leveraging internal and external resources to support business objectives and strategies while at the same time accounting for the diverse business, legal, privacy, regulatory and safety requirements across the globe to ensure efficiency, consistency and compliance.

In the new Astellas VISION, the company aims to turn innovative science into value for patients on the forefront of healthcare change. The establishment of the RWI function is a part of initiatives adopting the VISION and Astellas will leverage this function as its new capability.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

###